256 related articles for article (PubMed ID: 30650356)
1. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG
Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356
[TBL] [Abstract][Full Text] [Related]
2. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Id1 in transgenic mice promotes mammary basal stem cell activity and breast tumorigenesis.
Shin DH; Park JH; Lee JY; Won HY; Jang KS; Min KW; Jang SH; Woo JK; Oh SH; Kong G
Oncotarget; 2015 Jul; 6(19):17276-90. PubMed ID: 25938540
[TBL] [Abstract][Full Text] [Related]
4. Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer.
Vadakkan TJ; Landua JD; Bu W; Wei W; Li F; Wong ST; Dickinson ME; Rosen JM; Lewis MT; Zhang M
Stem Cells Transl Med; 2014 Jul; 3(7):857-66. PubMed ID: 24797826
[TBL] [Abstract][Full Text] [Related]
5. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis.
Pathania R; Ramachandran S; Elangovan S; Padia R; Yang P; Cinghu S; Veeranan-Karmegam R; Arjunan P; Gnana-Prakasam JP; Sadanand F; Pei L; Chang CS; Choi JH; Shi H; Manicassamy S; Prasad PD; Sharma S; Ganapathy V; Jothi R; Thangaraju M
Nat Commun; 2015 Apr; 6():6910. PubMed ID: 25908435
[TBL] [Abstract][Full Text] [Related]
6. SRC Increases
Abdullah C; Korkaya H; Iizuka S; Courtneidge SA
Mol Cell Biol; 2018 Mar; 38(6):. PubMed ID: 29263157
[TBL] [Abstract][Full Text] [Related]
7. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
8. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
9. Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis.
Moumen M; Chiche A; Decraene C; Petit V; Gandarillas A; Deugnier MA; Glukhova MA; Faraldo MM
Mol Cancer; 2013 Oct; 12(1):132. PubMed ID: 24171719
[TBL] [Abstract][Full Text] [Related]
10. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.
Chiche A; Di-Cicco A; Sesma-Sanz L; Bresson L; de la Grange P; Glukhova MA; Faraldo MM; Deugnier MA
Breast Cancer Res; 2019 Jan; 21(1):13. PubMed ID: 30683141
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.
Leung JY; Andrechek ER; Cardiff RD; Nevins JR
Oncogene; 2012 May; 31(20):2545-54. PubMed ID: 21996730
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.
Tosoni D; Pambianco S; Ekalle Soppo B; Zecchini S; Bertalot G; Pruneri G; Viale G; Di Fiore PP; Pece S
EMBO Mol Med; 2017 May; 9(5):655-671. PubMed ID: 28298340
[TBL] [Abstract][Full Text] [Related]
13. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
14. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
Jang JW; Boxer RB; Chodosh LA
Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
[TBL] [Abstract][Full Text] [Related]
15. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.
Akita H; Marquardt JU; Durkin ME; Kitade M; Seo D; Conner EA; Andersen JB; Factor VM; Thorgeirsson SS
Cancer Res; 2014 Oct; 74(20):5903-13. PubMed ID: 25189530
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of Myc in stem cell biology and novel tumor therapies.
Yoshida GJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
[TBL] [Abstract][Full Text] [Related]
17. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
[TBL] [Abstract][Full Text] [Related]
18. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.
Klinakis A; Szabolcs M; Politi K; Kiaris H; Artavanis-Tsakonas S; Efstratiadis A
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9262-7. PubMed ID: 16751266
[TBL] [Abstract][Full Text] [Related]
19. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.
Jamerson MH; Johnson MD; Dickson RB
Oncogene; 2000 Feb; 19(8):1065-71. PubMed ID: 10713691
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
